GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Piotroski F-Score

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Piotroski F-Score : 5 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

abrdn Life Sciences Investors has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for abrdn Life Sciences Investors's Piotroski F-Score or its related term are showing as below:

HQL' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 7 years, the highest Piotroski F-Score of abrdn Life Sciences Investors was 5. The lowest was 2. And the median was 4.


abrdn Life Sciences Investors Piotroski F-Score Historical Data

The historical data trend for abrdn Life Sciences Investors's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Piotroski F-Score Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Piotroski F-Score
Get a 7-Day Free Trial 4.00 5.00 2.00 3.00 5.00

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 - 3.00 - 5.00

Competitive Comparison of abrdn Life Sciences Investors's Piotroski F-Score

For the Asset Management subindustry, abrdn Life Sciences Investors's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's Piotroski F-Score Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was $22.35 Mil.
Cash Flow from Operations was $0.00 Mil.
Revenue was $23.52 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was (414.725 + 402.6) / 2 = $408.6625 Mil.
Total Assets at the begining of this year (Sep22) was $414.73 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Assets was $402.60 Mil.
Total Liabilities was $0.67 Mil.
Net Income was $-104.60 Mil.

Revenue was $-103.25 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was (534.185 + 414.725) / 2 = $474.455 Mil.
Total Assets at the begining of last year (Sep21) was $534.19 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Assets was $414.73 Mil.
Total Liabilities was $16.82 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

abrdn Life Sciences Investors's current Net Income (TTM) was 22.35. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

abrdn Life Sciences Investors's current Cash Flow from Operations (TTM) was 0.00. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=22.352/414.725
=0.05389596

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-104.603/534.185
=-0.19581793

abrdn Life Sciences Investors's return on assets of this year was 0.05389596. abrdn Life Sciences Investors's return on assets of last year was -0.19581793. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

abrdn Life Sciences Investors's current Net Income (TTM) was 22.35. abrdn Life Sciences Investors's current Cash Flow from Operations (TTM) was 0.00. ==> 0.00 <= 22.35 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0/408.6625
=0

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0/474.455
=0

abrdn Life Sciences Investors's gearing of this year was 0. abrdn Life Sciences Investors's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

* Note that for banks and insurance companies, there's no Total Current Assets and Total Current Liabilities reported. Thus, we use Total Assets and Total Liabilities to calculate current ratio for banks and insurance companies.

Current Ratio (This Year: Sep23)=Total Assets/Total Liabilities
=402.6/0.667
=603.5982009

Current Ratio (Last Year: Sep22)=Total Assets/Total Liabilities
=414.725/16.823
=24.65226178

abrdn Life Sciences Investors's current ratio of this year was 603.5982009. abrdn Life Sciences Investors's current ratio of last year was 24.65226178. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

abrdn Life Sciences Investors's number of shares in issue this year was 28.294. abrdn Life Sciences Investors's number of shares in issue last year was 24.555. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

* Note that for banks and insurance companies, there's no Gross Profit reported. Thus, we use net income instead of gross profit and calculate Net Margin for this score.

Net Margin (This Year: TTM)=Net Income/Revenue
=22.352/23.524
=0.95017854

Net Margin (Last Year: TTM)=Net Income/Revenue
=-104.603/-103.25
=1.01310412

abrdn Life Sciences Investors's net margin of this year was 0.95017854. abrdn Life Sciences Investors's net margin of last year was 1.01310412. ==> Last year's net margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=23.524/414.725
=0.05672192

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=-103.25/534.185
=-0.1932851

abrdn Life Sciences Investors's asset turnover of this year was 0.05672192. abrdn Life Sciences Investors's asset turnover of last year was -0.1932851. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

abrdn Life Sciences Investors has an F-score of 5 indicating the company's financial situation is typical for a stable company.

abrdn Life Sciences Investors  (NYSE:HQL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


abrdn Life Sciences Investors Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 01-06-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-15-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-16-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-30-2022

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 08-17-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 09-30-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-15-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 05-17-2022

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 05-18-2020